This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Bayer acquires Perfuse Therapeutics
Business acquisition

Bayer acquires Perfuse Therapeutics

Analysis based on 7 articles · First reported Jun 17, 2026 · Last updated Jun 17, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The acquisition of TherapeuticsMD by Bayer is expected to positively impact Bayer's stock due to the strengthening of its pharmaceutical pipeline and ophthalmology expertise. The deal also provides a significant financial gain for TherapeuticsMD and its stakeholders.

Pharmaceuticals Biotechnology
Event Summary

Bayer has completed the acquisition of TherapeuticsMD, Inc., integrating the biopharmaceutical company fully into its operations. This strategic move grants Bayer full rights to PER-001 intravitreal implant, a Phase II clinical development asset for Glaucoma and Diabetic Retinopathy. The transaction involved an upfront payment of USD 300 million, with a total potential value reaching up to USD 2.45 billion through additional success-based milestone payments. This acquisition is set to enhance Bayer's pharmaceutical pipeline and reinforce its position in ophthalmology.

Entities Involved
stock
TherapeuticsMD
TherapeuticsMD was acquired by Bayer for an upfront payment of USD 300 million and potential milestone payments up to USD 2.45 billion. It will be fully integrated into Bayer.
Importance 100.0 Sentiment 80.0
stock
Bayer
Bayer completed the acquisition of TherapeuticsMD, strengthening its pharmaceutical pipeline and ophthalmology expertise. This acquisition gives Bayer full rights to PER-001 intravitreal implant.
Importance 100.0 Sentiment 70.0
priv
Centerview Partners
Centerview Partners LLC acted as exclusive financial advisor for TherapeuticsMD in the acquisition.
Importance 20.0 Sentiment 10.0
priv
Goodwin Procter
Goodwin Procter LLP acted as legal counsel for TherapeuticsMD in the acquisition.
Importance 20.0 Sentiment 10.0
priv
Baker McKenzie
Baker McKenzie acted as legal counsel for Bayer in the acquisition.
Importance 20.0 Sentiment 10.0
stock
Meritz Securities
Meritz Securities acted as exclusive financial advisor for Bayer in the acquisition.
Importance 20.0 Sentiment 10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.